Guangzhou Wondfo Biotech Co Ltd (SHE:300482) — Market Cap & Net Worth
Market Cap & Net Worth: Guangzhou Wondfo Biotech Co Ltd (300482)
Guangzhou Wondfo Biotech Co Ltd (SHE:300482) has a market capitalization of $1.25 Billion (CN¥8.56 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #8139 globally and #2057 in its home market, demonstrating a 4.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangzhou Wondfo Biotech Co Ltd's stock price CN¥18.29 by its total outstanding shares 468084909 (468.08 Million). Analyse cash efficiency ratio of Guangzhou Wondfo Biotech Co Ltd to see how efficiently the company converts income to cash.
Guangzhou Wondfo Biotech Co Ltd Market Cap History: 2015 to 2026
Guangzhou Wondfo Biotech Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.67 Billion to $1.25 Billion (0.64% CAGR).
Guangzhou Wondfo Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangzhou Wondfo Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.50x
Guangzhou Wondfo Biotech Co Ltd's market cap is 0.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.73x
Guangzhou Wondfo Biotech Co Ltd's market cap is 2.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.67 Billion | $428.78 Million | $125.35 Million | 3.89x | 13.29x |
| 2016 | $2.04 Billion | $547.35 Million | $144.99 Million | 3.73x | 14.09x |
| 2017 | $2.02 Billion | $1.15 Billion | $210.70 Million | 1.77x | 9.61x |
| 2018 | $1.27 Billion | $1.65 Billion | $307.74 Million | 0.77x | 4.12x |
| 2019 | $2.60 Billion | $2.07 Billion | $387.46 Million | 1.26x | 6.72x |
| 2020 | $4.50 Billion | $2.81 Billion | $634.17 Million | 1.60x | 7.10x |
| 2021 | $2.60 Billion | $3.36 Billion | $634.43 Million | 0.77x | 4.09x |
| 2022 | $2.12 Billion | $5.68 Billion | $1.20 Billion | 0.37x | 1.77x |
| 2023 | $2.04 Billion | $2.76 Billion | $487.62 Million | 0.74x | 4.18x |
| 2024 | $1.53 Billion | $3.06 Billion | $561.63 Million | 0.50x | 2.73x |
Competitor Companies of 300482 by Market Capitalization
Companies near Guangzhou Wondfo Biotech Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Guangzhou Wondfo Biotech Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Guangzhou Wondfo Biotech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangzhou Wondfo Biotech Co Ltd's market cap moved from $1.67 Billion to $ 1.25 Billion, with a yearly change of 0.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.25 Billion | -7.39% |
| 2025 | CN¥1.35 Billion | -11.87% |
| 2024 | CN¥1.53 Billion | -24.64% |
| 2023 | CN¥2.04 Billion | -3.76% |
| 2022 | CN¥2.12 Billion | -18.46% |
| 2021 | CN¥2.60 Billion | -42.31% |
| 2020 | CN¥4.50 Billion | +72.84% |
| 2019 | CN¥2.60 Billion | +105.10% |
| 2018 | CN¥1.27 Billion | -37.30% |
| 2017 | CN¥2.02 Billion | -0.89% |
| 2016 | CN¥2.04 Billion | +22.59% |
| 2015 | CN¥1.67 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Guangzhou Wondfo Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Billion USD |
| MoneyControl | $1.25 Billion USD |
| MarketWatch | $1.25 Billion USD |
| marketcap.company | $1.25 Billion USD |
| Reuters | $1.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more